1. Home
  2. PUBM vs RIGL Comparison

PUBM vs RIGL Comparison

Compare PUBM & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PUBM
  • RIGL
  • Stock Information
  • Founded
  • PUBM 2006
  • RIGL 1996
  • Country
  • PUBM United States
  • RIGL United States
  • Employees
  • PUBM N/A
  • RIGL N/A
  • Industry
  • PUBM Computer Software: Prepackaged Software
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • PUBM Technology
  • RIGL Health Care
  • Exchange
  • PUBM Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • PUBM 382.7M
  • RIGL 335.5M
  • IPO Year
  • PUBM 2020
  • RIGL 2000
  • Fundamental
  • Price
  • PUBM $8.26
  • RIGL $29.74
  • Analyst Decision
  • PUBM Buy
  • RIGL Buy
  • Analyst Count
  • PUBM 11
  • RIGL 5
  • Target Price
  • PUBM $18.05
  • RIGL $38.20
  • AVG Volume (30 Days)
  • PUBM 569.1K
  • RIGL 644.0K
  • Earning Date
  • PUBM 11-11-2025
  • RIGL 11-06-2025
  • Dividend Yield
  • PUBM N/A
  • RIGL N/A
  • EPS Growth
  • PUBM N/A
  • RIGL N/A
  • EPS
  • PUBM N/A
  • RIGL 5.43
  • Revenue
  • PUBM $292,208,000.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • PUBM N/A
  • RIGL $59.93
  • Revenue Next Year
  • PUBM $1.40
  • RIGL N/A
  • P/E Ratio
  • PUBM N/A
  • RIGL $5.42
  • Revenue Growth
  • PUBM 3.53
  • RIGL 105.62
  • 52 Week Low
  • PUBM $7.01
  • RIGL $13.57
  • 52 Week High
  • PUBM $17.74
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • PUBM 44.09
  • RIGL 40.10
  • Support Level
  • PUBM $8.19
  • RIGL $27.75
  • Resistance Level
  • PUBM $8.58
  • RIGL $29.46
  • Average True Range (ATR)
  • PUBM 0.30
  • RIGL 1.51
  • MACD
  • PUBM 0.05
  • RIGL -0.41
  • Stochastic Oscillator
  • PUBM 22.73
  • RIGL 26.27

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: